Ipamorelin vs GHRP-6: Research Comparison Guide 2026

# Ipamorelin vs GHRP-6: Research Comparison Guide 2026

> Disclaimer: This article is for educational and research purposes only. Ipamorelin and GHRP-6 are research peptides sold exclusively for in vitro and laboratory use. They are not approved for human consumption, therapeutic use, or self-administration.

Among growth hormone-releasing peptides (GHRPs), Ipamorelin and GHRP-6 occupy different positions on the selectivity spectrum. Both stimulate GH release via the ghrelin receptor (GHS-R1a), but their ancillary hormonal effects -- particularly on cortisol, prolactin, and appetite -- differ substantially. This distinction has made them the subject of direct comparison studies and makes the choice between them consequential for research protocol design.

---

Quick Comparison Table

---

Background: The GHRP Family

GHRPs are synthetic peptides that stimulate GH release by acting as agonists at the growth hormone secretagogue receptor (GHS-R1a) -- the same receptor activated by ghrelin, the gut-derived "hunger hormone." This mechanism is distinct from GHRH analogs like CJC-1295 and Sermorelin, which act on the GHRH receptor.

GHRP generations:

• •1st generation: GHRP-1 (first synthetic GHS, Bowers 1980)
• •2nd generation: GHRP-2, GHRP-6 (improved potency; significant cortisol/prolactin effects)
• •3rd generation: Ipamorelin, Hexarelin (enhanced selectivity, reduced off-target effects)

The evolutionary arc of GHRP research was specifically aimed at improving GH selectivity -- reducing the cortisol, prolactin, and appetite-stimulating effects that complicate earlier GHRPs.

---

GHRP-6: Research Profile

Structure and Pharmacology

GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide developed in the laboratory of Cyril Bowers at Tulane University in the 1980s. It represents the prototypical second-generation GHRP and was among the first GHS compounds used extensively in both animal and human research.

GHRP-6 activates GHS-R1a with high affinity but also engages CD36 (a scavenger receptor involved in lipid metabolism) and has been shown to interact with opioid receptor pathways at higher concentrations. This broad receptor interaction profile explains its more complex hormonal effects.

Cortisol and ACTH Effects

GHRP-6's most significant limitation for certain research applications. Multiple studies have documented that GHRP-6 administration significantly elevates:

• •Cortisol: ~2-3x baseline increases in human studies
• •ACTH: Moderate elevation, ~1.5-2x baseline
• •Prolactin: Moderate elevation, up to 2x baseline

Appetite and Ghrelin-Like Effects

GHRP-6's activation of GHS-R1a closely mimics ghrelin signaling, producing potent appetite stimulation. Wren et al. (2001) demonstrated that peripheral GHRP-6 administration increased food intake in rodents by 30-40% over controls.

Key Research Findings

GH pulse characterization:

Cardiac cytoprotection research:

Wound healing research:

---

Ipamorelin: Research Profile

Structure and Pharmacology

Ipamorelin (Aib-His-D-2Nal-D-Phe-Lys-NH2) was developed by Novo Nordisk in the late 1990s and published by Raun et al. (1998) as a breakthrough in selective GHS compounds. Its key structural feature is the use of D-2-naphthylalanine (D-2Nal) at position 3, which confers high GHS-R1a selectivity while minimizing interactions with other receptor systems.

Ipamorelin is classified as a third-generation GHRP due to its dramatically improved endocrine selectivity: it stimulates GH release without significantly affecting cortisol, prolactin, ACTH, or TSH.

GH Release Selectivity

The defining advantage of ipamorelin is GH selectivity. Raun et al. (1998) directly compared ipamorelin, GHRP-2, GHRP-6, and hexarelin in rats, demonstrating that ipamorelin produced GH pulses comparable to GHRP-6 while producing no significant change in plasma cortisol, ACTH, or prolactin (PMID: 9849822). This study established ipamorelin as the gold standard for GH-selective GHRP research.

Key Research Findings

Selectivity characterization:

Raun et al. (1998): In conscious swine, ipamorelin produced GH pulses at 3-10 nM concentrations without significant cortisol, ACTH, or prolactin elevation -- demonstrating the clean endocrine profile that defines the compound (PMID: 9849822).

GH pulse and IGF-1:

Bone formation research:

---

Head-to-Head: Ipamorelin vs GHRP-6

Cortisol and Stress Hormone Profile

This is the most consequential difference:

For any research where cortisol confounding would invalidate results -- body composition, adipose tissue research, immune function, metabolic rate studies -- ipamorelin is the appropriate choice.

GHRP Selectivity Spectrum

Research Applications by Compound

Choose Ipamorelin for:

• •Pure GH axis research where cortisol confounding is unacceptable
• •Long-duration studies where cortisol normalization between doses is important
• •Body composition research (lean mass, fat mass endpoints)
• •Bone metabolism and formation studies
• •Standard GHRP component in CJC-1295 + GHRP stacks
• •Any protocol requiring maximum GH selectivity

Choose GHRP-6 for:

• •Multi-axis endocrine stimulation studies
• •Cardiac cytoprotection research (CD36-mediated mechanisms)
• •Appetite regulation research
• •Wound healing and tissue repair studies (CD36/PPAR-gamma pathway)
• •Historical comparison with extensive GHRP-6 clinical literature
• •Cost-sensitive research where selectivity is less critical

---

Pricing Comparison

Based on current supplier data from our marketplace (April 2026):

GHRP-6 is generally more affordable than ipamorelin, reflecting its longer production history and higher synthesis volume. Ipamorelin commands a modest premium due to its more complex synthesis (D-2Nal residue) and selectivity advantage.

Compare current pricing at Peptides.SO GHRP-6 listings and Ipamorelin listings.

---

Summary

Ipamorelin and GHRP-6 both stimulate GH release via GHS-R1a, but their off-target endocrine profiles differ substantially. GHRP-6 produces broad hormonal activation including significant cortisol, prolactin, and appetite stimulation -- properties that limit its GH specificity but create valuable research niches in cardioprotection, wound healing, and appetite modulation. Ipamorelin is the gold standard for GH-selective research, producing clean GH pulses without cortisol, prolactin, or significant appetite effects -- making it the preferred GHRP in most modern GH axis research protocols.

For most applications, ipamorelin is the superior choice for isolated GH research, while GHRP-6 remains relevant for multi-pathway studies.

---

This article is for research and educational purposes only. These compounds are not approved for human use.

Further Reading:

• •GHRPs Compared: Full 4-Way Analysis
• •CJC-1295 vs Sermorelin Comparison
• •Ipamorelin vs GHRP-2 Research Guide
• •Peptide Stack Builder

---

Further Reading:

• •CJC-1295 vs Sermorelin: Research Comparison Guide 2026
• •GHRPs Compared: GHRP-2 vs GHRP-6 vs Ipamorelin vs Hexarelin — A Complete Research Guide (2026)
• •CJC-1295 + Ipamorelin Stack Guide: Dosing, Cost Analysis, and Where to Buy (2026)
• •Best Peptides for Muscle Growth Research: Growth Hormone Secretagogues (2026)
• •Peptide Stack Builder
• •Dosage Chart

References

• •PMID: 42395176
• •PMID: 32257855
• •PMID: 30282322